Michaela Kaiserova

Dr. Michaela Kaiserova

1. Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2023 in Journal of Neurochemistry
Verified
Journal Article
Open access
DKDorota Koníčková
Dorota Koníčková
KMKateřina Menšíková
Kateřina Menšíková
KKKateřina Klíčová
Kateřina Klíčová
MCMonika Chudáčková
Monika Chudáčková
MKMichaela Kaiserova
Michaela Kaiserova
PKPetr Kanovsky
Petr Kanovsky
Neurodegenerative diseases are a broad heterogeneous group affecting the nervous system. They are characterized, from a pathophysiological perspective, by the selective involvement of a subpopulation of nerve cells with a consequent clinical picture of a disease. Clinical diagnoses of neurodegenerative diseases are quite challenging and often not completely accurate because of their marked heterogeneity and frequently overlapping clinical pictures. Efforts are being made to define sufficiently specific and sensitive markers for individual neurodegenerative diseases or groups of diseases in order to increase the accuracy and speed of clinical diagnosis. Thus said, this present research aimed to identify biomarkers in the cerebrospinal fluid (CSF) and serum (α‐synuclein [α‐syn], tau protein [t‐tau], phosphorylated tau protein [p‐tau], β‐amyloid [Aβ], clusterin, chromogranin A [chromogrA], cystatin C [cyst C], neurofilament heavy chains [NFH], phosphorylated form of neurofilament heavy chains [pNF‐H], and ratio of tau protein/amyloid beta [Ind tau/Aβ]) that could help in the differential diagnosis and differentiation of the defined groups of α‐synucleinopathies and four‐repeat (4R‐) tauopathies characterized by tau protein isoforms with four microtubule‐binding domains. In this study, we analyzed a cohort of 229 patients divided into four groups: (1) Parkinson's disease (PD) + dementia with Lewy bodies (DLB) (n = 82), (2) multiple system atrophy (MSA) (n = 25), (3) progressive supranuclear palsy (PSP) + corticobasal syndrome (CBS) (n = 30), and (4) healthy controls (HC) (n = 92). We also focused on analyzing the biomarkers in relation to each other with the intention of determining whether they are useful in distinguishing among individual proteinopathies. Our results indicate that the proposed set of biomarkers, when evaluated in CSF, is likely to be useful for the differential diagnosis of MSA versus 4RT. However, these biomarkers do not seem to provide any useful diagnostic information when assessed in blood serum. image

10 February 2017 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
MKMichaela Kaiserova
Michaela Kaiserova
ZGZ. Grambalova
Z. Grambalova
POP. Otruba
P. Otruba
David StejskalDavid Stejskal
David Stejskal
HVH. Prikrylova Vranova
H. Prikrylova Vranova
PKP. Kanovsky
P. Kanovsky

22 January 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MKMichaela Kaiserova
Michaela Kaiserova
MCMonika Chudackova
Monika Chudackova
KMKaterina Mensikova
Katerina Mensikova
MVMiroslav Vastik
Miroslav Vastik
SKSandra Kurcova
Sandra Kurcova
PKPetr Kanovsky
Petr Kanovsky
Background: Chromogranin A (CgA) and other peptides from the chromogranin–secretogranin family have been recently studied as potential biomarkers of various neurodegenerative diseases, including Parkinson’s disease (PD). Methods: We measured CgA in the cerebrospinal fluid (CSF) of 119 PD patients, 18 multiple system atrophy (MSA) patients, and 31 age-matched controls. We also correlated the values with disease duration and levodopa dose equivalent. Results: In the PD patients, CSF CgA tended to be lower than the control group (median 124.5 vs. 185.2 µg/L; p = 0.057); however, the results did not reach statistical significance. CSF CgA levels in MSA were significantly lower compared to the control group (median 104.4 vs. 185.2; p = 0.014). There was no significant difference in CSF CgA between PD and MSA patients (p = 0.372). There was no association between CSF CgA and disease duration or levodopa dose equivalent in PD or in MSA. Conclusions: We observed a tendency toward lower CSF CgA levels in both PD and MSA compared to the control group; however, the difference reached statistical significance only in MSA. Based on these results, CgA may have potential as a biomarker in PD and MSA, but further studies on larger numbers of patients are needed to draw conclusions.

16 April 2013 in Journal of Neural Transmission
Verified
Journal Article
Closed access
PDF file
MKMichaela Kaiserova
Michaela Kaiserova
HVHana Přikrylová Vranová
Hana Přikrylová Vranová
David StejskalDavid Stejskal
David Stejskal
KMKateřina Menšíková
Kateřina Menšíková
PKPetr Kaňovský
Petr Kaňovský

10 September 2015 in Clinical Autonomic Research
Verified
Journal Article
Closed access
PDF file
MKMichaela Kaiserova
Michaela Kaiserova
HVHana Prikrylova Vranova
Hana Prikrylova Vranova
JGJan Galuszka
Jan Galuszka
David StejskalDavid Stejskal
David Stejskal
KMKaterina Mensikova
Katerina Mensikova
PKPetr Kanovsky
Petr Kanovsky

27 October 2021 in International Journal of Neuroscience
Verified
Journal Article
Closed access
MKMichaela Kaiserova
Michaela Kaiserova
AKAnetta Kastelikova
Anetta Kastelikova
ZGZuzana Grambalova
Zuzana Grambalova
POPavel Otruba
Pavel Otruba
JZJana Zapletalova
Jana Zapletalova
PKPetr Kanovsky
Petr Kanovsky
The pathophysiology of abnormal temperature sensation in Parkinson’s disease (PD) remains unclear. Abnormal thermal detection does not seem to depend on the dopaminergic deficit, suggesting that ot...